On Thursday, the FDA approved Human Genome Sciences’ Benlysta (Belimumab) drug for the treatment of Lupus. This is the first new treatment for lupus in decades.
It is widely expected that Benlysta will be a certified blockbuster with peak-year sales of between $2.5-$3.1 billion per year.
Human Genome Sciences and its marketing partner GlaxoSmithKline anticipate the drug to be available by the end of March.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment